These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33558424)

  • 1. Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer.
    Lee IS; Lee H; Hur H; Kanda M; Yook JH; Kim BS; Woo Y; Kodera Y; Kim K; Goel A
    Clin Cancer Res; 2021 Apr; 27(8):2292-2300. PubMed ID: 33558424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer.
    Ding P; Wu H; Wu J; Li T; Gu R; Zhang L; Yang P; Guo H; Tian Y; He J; Yang J; Meng N; Li X; Meng L; Zhao Q
    J Exp Clin Cancer Res; 2024 Jun; 43(1):181. PubMed ID: 38937855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
    Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
    Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
    Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
    Front Immunol; 2021; 12():651033. PubMed ID: 34054812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients With Gastric Cancer.
    Shimura T; Toden S; Kandimalla R; Toiyama Y; Okugawa Y; Kanda M; Baba H; Kodera Y; Kusunoki M; Goel A
    Ann Surg; 2021 Nov; 274(5):e425-e434. PubMed ID: 31663973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT.
    Hu Q; Masuda T; Kuramitsu S; Tobo T; Sato K; Kidogami S; Nambara S; Ueda M; Tsuruda Y; Kuroda Y; Ito S; Oki E; Mori M; Mimori K
    PLoS One; 2020; 15(10):e0241140. PubMed ID: 33095806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer.
    Kanda M; Shimizu D; Tanaka H; Tanaka C; Kobayashi D; Hayashi M; Iwata N; Niwa Y; Yamada S; Fujii T; Sugimoto H; Murotani K; Fujiwara M; Kodera Y
    Ann Surg; 2018 Mar; 267(3):495-503. PubMed ID: 28026832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Peritoneal Metastasis of Gastric Cancer Patients Based on Machine Learning.
    Zhou C; Wang Y; Ji MH; Tong J; Yang JJ; Xia H
    Cancer Control; 2020; 27(1):1073274820968900. PubMed ID: 33115287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer.
    Sawaki K; Kanda M; Miwa T; Umeda S; Tanaka H; Tanaka C; Kobayashi D; Suenaga M; Hattori N; Hayashi M; Yamada S; Nakayama G; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2018 Jul; 25(7):2083-2090. PubMed ID: 29663169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
    Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Eur J Cancer; 2022 Mar; 163():66-76. PubMed ID: 35042069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer.
    Tokuhisa M; Ichikawa Y; Kosaka N; Ochiya T; Yashiro M; Hirakawa K; Kosaka T; Makino H; Akiyama H; Kunisaki C; Endo I
    PLoS One; 2015; 10(7):e0130472. PubMed ID: 26208314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of cancer cells exposed to gastric serosa by serosal stamp cytology plus RT-PCR is useful for the identification of gastric cancer patients at high risk of peritoneal recurrence.
    Miki Y; Yashiro M; Ando K; Okuno T; Kitayama K; Masuda G; Tamura T; Sakurai K; Toyokawa T; Kubo N; Tanaka H; Muguruma K; Osawa M; Hirakawa K; Ohira M
    Surg Oncol; 2017 Dec; 26(4):352-358. PubMed ID: 29113652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.
    Yang Y; Qu A; Zhao R; Hua M; Zhang X; Dong Z; Zheng G; Pan H; Wang H; Yang X; Zhang Y
    Mol Oncol; 2018 Dec; 12(12):2072-2084. PubMed ID: 30242969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating microRNA-203 predicts metastases, early recurrence, and poor prognosis in human gastric cancer.
    Imaoka H; Toiyama Y; Okigami M; Yasuda H; Saigusa S; Ohi M; Tanaka K; Inoue Y; Mohri Y; Kusunoki M
    Gastric Cancer; 2016 Jul; 19(3):744-53. PubMed ID: 26233325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer.
    Takeno A; Takemasa I; Seno S; Yamasaki M; Motoori M; Miyata H; Nakajima K; Takiguchi S; Fujiwara Y; Nishida T; Okayama T; Matsubara K; Takenaka Y; Matsuda H; Monden M; Mori M; Doki Y
    Ann Surg Oncol; 2010 Apr; 17(4):1033-42. PubMed ID: 20012501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer.
    Dong ZB; Xiang HT; Wu HM; Cai XL; Chen ZW; Chen SS; He YC; Li H; Yu WM; Liang C
    Gastric Cancer; 2023 Nov; 26(6):947-957. PubMed ID: 37691031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer.
    Shin SJ; Park S; Kim MH; Nam CM; Kim H; Choi YY; Jung MK; Choi HJ; Rha SY; Chung HC
    Oncologist; 2019 Nov; 24(11):e1108-e1114. PubMed ID: 31015316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting peritoneal recurrence after radical gastrectomy for gastric cancer: Validation of a prediction model (PERI-Gastric 1 and PERI-Gastric 2) on a Korean database.
    Belia F; Kim KY; Agnes A; Park SH; Cho M; Kim YM; Kim HI; Persiani R; D'Ugo D; Biondi A; Hyung WJ
    Eur J Surg Oncol; 2024 Jun; 50(6):108359. PubMed ID: 38657377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.